|
1
|
Zhou G, Bao ZQ and Dixon JE: Components of
a new human protein kinase signal transduction pathway. J Biol
Chem. 270:12665–12669. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
English JM, Vanderbilt CA, Xu S, Marcus S
and Cobb MH: Isolation of MEK5 and differential expression of
alternatively spliced forms. J Biol Chem. 270:28897–28902. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dinev D, Jordan BW, Neufeld B, Lee JD,
Lindemann D, Rapp UR and Ludwig S: Extracellular signal regulated
kinase 5 (ERK5) is required for the differentiation of muscle
cells. EMBO Rep. 2:829–834. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shalizi A, Lehtinen M, Gaudilliere B,
Donovan N, Han J, Konishi Y and Bonni A: Characterization of a
neurotrophin signaling mechanism that mediates neuron survival in a
temporally specific pattern. J Neurosci. 23:7326–7336.
2003.PubMed/NCBI
|
|
5
|
Liu L, Cavanaugh JE, Wang Y, Sakagami H,
Mao Z and Xia Z: ERK5 activation of MEF2-mediated gene expression
plays a critical role in BDNF-promoted survival of developing but
not mature cortical neurons. Proc Natl Acad Sci USA. 100:8532–8537.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kato Y, Kravchenko VV, Tapping RI, Han J,
Ulevitch RJ and Lee JD: BMK1/ERK5 regulates serum-induced early
gene expression through transcription factor MEF2C. EMBO J.
16:7054–7066. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang X, Merritt AJ, Seyfried J, Guo C,
Papadakis ES, Finegan KG, Kayahara M, Dixon J, Boot-Handford RP,
Cartwright EJ, et al: Targeted deletion of mek5 causes early
embryonic death and defects in the extracellular signal-regulated
kinase 5/myocyte enhancer factor 2 cell survival pathway. Mol Cell
Biol. 25:336–345. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yan L, Carr J, Ashby PR, Murry-Tait V,
Thompson C and Arthur JS: Knockout of ERK5 causes multiple defects
in placental and embryonic development. BMC Dev Biol. 3:11–32.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Terasawa K, Okazaki K and Nishida E:
Regulation of c-Fos and Fra-1 by the MEK5-ERK5 pathway. Genes
Cells. 8:263–273. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pearson G, English JM, White MA and Cobb
MH: ERK5 and ERK2 cooperate to regulate NF-kappaB and cell
transformation. J Biol Chem. 276:7927–7931. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kato Y, Zhao M, Morikawa A, Sugiyama T,
Chakravortty D, Koide N, Yoshida T, Tapping RI, Yang Y, Yokochi T,
et al: Big mitogen-activated kinase regulates multiple members of
the MEF2 protein family. J Biol Chem. 275:18534–18540. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lochhead PA, Gilley R and Cook SJ: ERK5
and its role in tumour development. Biochem Soc Trans. 40:251–256.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Drew BA, Burow ME and Beckman BS:
MEK5/ERK5 pathway: The first fifteen years. Biochim Biophys Acta.
1825:37–48. 2012.PubMed/NCBI
|
|
14
|
Mehta PB, Jenkins BL, McCarthy L, Thilak
L, Robson CN, Neal DE and Leung HY: MEK5 overexpression is
associated with metastatic prostate cancer, and stimulates
proliferation, MMP-9 expression and invasion. Oncogene.
22:1381–1389. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ramsay AK, McCracken SR, Soofi M, Fleming
J, Yu AX, Ahmad I, Morland R, Machesky L, Nixon C, Edwards DR, et
al: ERK5 signalling in prostate cancer promotes an invasive
phenotype. Br J Cancer. 104:664–672. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou C, Nitschke AM, Xiong W, Zhang Q,
Tang Y, Bloch M, Elliott S, Zhu Y, Bazzone L, Yu D, et al:
Proteomic analysis of tumor necrosis factor-alpha resistant human
breast cancer cells reveals a MEK5/Erk5-mediated
epithelial-mesenchymal transition phenotype. Breast Cancer Res.
10:R1052008. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qiu F, Yang L, Fang W, Li Y, Yang R, Yang
X, Deng J, Huang B, Xie C, Zhou Y, et al: A functional polymorphism
in the promoter of ERK5 gene interacts with tobacco smoking to
increase the risk of lung cancer in Chinese populations.
Mutagenesis. 28:561–567. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Diao D, Wang L, Wan J, Chen Z, Peng J, Liu
H, Chen X, Wang W and Zou L: MEK5 overexpression is associated with
the occurrence and development of colorectal cancer. BMC Cancer.
16:3022016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Simões AE, Pereira DM, Gomes SE, Brito H,
Carvalho T, French A, Castro RE, Steer CJ, Thibodeau SN, Rodrigues
CM, et al: Aberrant MEK5/ERK5 signalling contributes to human colon
cancer progression via NF-κB activation. Cell Death Dis.
6:e17182015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mansour MA, Hyodo T, Ito S, Kurita K,
Kokuryo T, Uehara K, Nagino M, Takahashi M, Hamaguchi M and Senga
T: SATB2 suppresses the progression of colorectal cancer cells via
inactivation of MEK5/ERK5 signaling. FEBS J. 282:1394–1405. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang X, Pesakhov S, Harrison JS, Danilenko
M and Studzinski GP: ERK5 pathway regulates transcription factors
important for monocytic differentiation of human myeloid leukemia
cells. J Cell Physiol. 229:856–867. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Umapathy G, El Wakil A, Witek B, Chesler
L, Danielson L, Deng X, Gray NS, Johansson M, Kvarnbrink S, Ruuth
K, et al: The kinase ALK stimulates the kinase ERK5 to promote the
expression of the oncogene MYCN in neuroblastoma. Sci Signal.
7:ra1022014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Giurisato E and Tournier C: Can tumor
cells proliferate without ERK5? Cell Cycle. 15:619–620. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Antoon JW, Martin EC, Lai R, Salvo VA,
Tang Y, Nitzchke AM, Elliott S, Nam SY, Xiong W, Rhodes LV, et al:
MEK5/ERK5 signaling suppresses estrogen receptor expression and
promotes hormone-independent tumorigenesis. PLoS One. 8:e692912013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li J, Dong L, Wei D, Wang X, Zhang S and
Li H: Fatty acid synthase mediates the epithelial-mesenchymal
transition of breast cancer cells. Int J Biol Sci. 10:171–180.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoshizumi M, Abe J, Tsuchiya K, Berk BC
and Tamaki T: Stress and vascular responses: atheroprotective
effect of laminar fluid shear stress in endothelial cells: possible
role of mitogen-activated protein kinases. J Pharmacol Sci.
91:172–176. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dent P, Yacoub A, Fisher PB, Hagan MP and
Grant S: MAPK pathways in radiation responses. Oncogene.
22:5885–5896. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chayama K, Papst PJ, Garrington TP, Pratt
JC, Ishizuka T, Webb S, Ganiatsas S, Zon LI, Sun W, Johnson GL, et
al: Role of MEKK2-MEK5 in the regulation of TNF-alpha gene
expression and MEKK2-MKK7 in the activation of c-Jun N-terminal
kinase in mast cells. Proc Natl Acad Sci USA. 98:4599–4604. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chao TH, Hayashi M, Tapping RI, Kato Y and
Lee JD: MEKK3 directly regulates MEK5 activity as part of the big
mitogen-activated protein kinase 1 (BMK1) signaling pathway. J Biol
Chem. 274:36035–36038. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun W, Kesavan K, Schaefer BC, Garrington
TP, Ware M, Johnson NL, Gelfand EW and Johnson GL: MEKK2 associates
with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5
pathway. J Biol Chem. 276:5093–5100. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Song H, Jin X and Lin J: Stat3 upregulates
MEK5 expression in human breast cancer cells. Oncogene.
23:8301–8309. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Miranda M, Rozali E, Khanna KK and Al-Ejeh
F: MEK5-ERK5 pathway associates with poor survival of breast cancer
patients after systemic treatments. Oncoscience. 2:99–101. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ortiz-Ruiz MJ, Álvarez-Fernández S,
Parrott T, Zaknoen S, Burrows FJ, Ocaña A, Pandiella A and
Esparís-Ogando A: Therapeutic potential of ERK5 targeting in triple
negative breast cancer. Oncotarget. 5:11308–11318. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Al-Ejeh F, Miranda M, Shi W, Simpson PT,
Song S, Vargas AC, Saunus JM, Smart CE, Mariasegaram M, Wiegmans
AP, et al: Kinome profiling reveals breast cancer heterogeneity and
identifies targeted therapeutic opportunities for triple negative
breast cancer. Oncotarget. 5:3145–3158. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Javaid S, Zhang J, Smolen GA, Yu M,
Wittner BS, Singh A, Arora KS, Madden MW, Desai R, Zubrowski MJ, et
al: MAPK7 regulates EMT features and modulates the generation of
CTCs. Mol Cancer Res. 13:934–943. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li JQ, Xue H, Zhou L, Dong LH, Wei DP and
Li H: Mechanism of fatty acid synthase in drug tolerance related to
epithelial-mesenchymal transition of breast cancer. Asian Pac J
Cancer Prev. 15:7617–7623. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Song H, Ethier SP, Dziubinski ML and Lin
J: Stat3 modulates heat shock 27kDa protein expression in breast
epithelial cells. Biochem Biophys Res Commun. 314:143–150. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q,
Tang F, Chen ZQ, Liu XP and Xu ZD: Twist1-mediated
adriamycin-induced epithelial-mesenchymal transition relates to
multidrug resistance and invasive potential in breast cancer cells.
Clin Cancer Res. 15:2657–2665. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kumar A, Xu J, Brady S, Gao H, Yu D,
Reuben J and Mehta K: Tissue transglutaminase promotes drug
resistance and invasion by inducing mesenchymal transition in
mammary epithelial cells. PLoS One. 5:e133902010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD
and Wang LH: Twist transcriptionally up-regulates AKT2 in breast
cancer cells leading to increased migration, invasion, and
resistance to paclitaxel. Cancer Res. 67:1979–1987. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Song H, Wang R, Wang S and Lin J: A
low-molecular-weight compound discovered through virtual database
screening inhibits Stat3 function in breast cancer cells. Proc Natl
Acad Sci USA. 102:4700–4705. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Villalva C, Martin-Lannerée S, Cortes U,
Dkhissi F, Wager M, Le Corf A, Tourani JM, Dusanter-Fourt I, Turhan
AG and Karayan-Tapon L: STAT3 is essential for the maintenance of
neurosphere-initiating tumor cells in patients with glioblastomas:
A potential for targeted therapy? Int J Cancer. 128:826–838. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Denysenko T, Gennero L, Roos MA, Melcarne
A, Juenemann C, Faccani G, Morra I, Cavallo G, Reguzzi S,
Pescarmona G, et al: Glioblastoma cancer stem cells: Heterogeneity,
microenvironment and related therapeutic strategies. Cell Biochem
Funct. 28:343–351. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lee JH, Jung C, Javadian-Elyaderani P,
Schweyer S, Schütte D, Shoukier M, Karimi-Busheri F, Weinfeld M,
Rasouli-Nia A, Hengstler JG, et al: Pathways of proliferation and
antiapoptosis driven in breast cancer stem cells by stem cell
protein piwil2. Cancer Res. 70:4569–4579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Honoki K, Fujii H, Kubo A, Kido A, Mori T,
Tanaka Y and Tsujiuchi T: Possible involvement of stem-like
populations with elevated ALDH1 in sarcomas for chemotherapeutic
drug resistance. Oncol Rep. 24:501–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Masuda M, Wakasaki T, Suzui M, Toh S, Joe
AK and Weinstein IB: Stat3 orchestrates tumor development and
progression: The Achilles heel of head and neck cancers? Curr
Cancer Drug Targets. 10:117–126. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yao Z and Mishra L: Cancer stem cells and
hepatocellular carcinoma. Cancer Biol Ther. 8:1691–1698. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang
Z, Yang CJ, Yuan L and Ouyang G: Twist2 contributes to breast
cancer progression by promoting an epithelial-mesenchymal
transition and cancer stem-like cell self-renewal. Oncogene.
30:4707–4720. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hii CS, Anson DS, Costabile M, Mukaro V,
Dunning K and Ferrante A: Characterization of the MEK5-ERK5 module
in human neutrophils and its relationship to ERK1/ERK2 in the
chemotactic response. J Biol Chem. 279:49825–49834. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sato Y, Harada K, Kizawa K, Sanzen T,
Furubo S, Yasoshima M, Ozaki S, Ishibashi M and Nakanuma Y:
Activation of the MEK5/ERK5 cascade is responsible for biliary
dysgenesis in a rat model of Carolis disease. Am J Pathol.
166:49–60. 2005. View Article : Google Scholar : PubMed/NCBI
|
